Loading…
Underlying
Underlying Price
$8.48
Type
Put
Strike
17
Expiration
Jan 19, 2029
DTE
822d
Moneyness
ITM
Intrinsic
$8.52
IBRX 17 Put Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | — | — | 0 | 0 |
| Oct 30, 2026 | 10d | — | — | 0 | 0 |
| Nov 6, 2026 | 17d | — | — | 0 | 0 |
| Nov 13, 2026 | 24d | — | — | 0 | 0 |
| Nov 20, 2026 | 31d | — | — | 0 | 0 |
| Nov 27, 2026 | 38d | — | — | 0 | 0 |
| Dec 18, 2026 | 59d | — | — | 0 | 0 |
| Jan 15, 2027 | 87d | $7.75 | +2.24% | 56 | 92 |
| Mar 19, 2027 | 150d | — | — | 0 | 0 |
| Apr 16, 2027 | 178d | — | — | 0 | 0 |
| May 21, 2027 | 213d | — | — | 0 | 0 |
| Aug 20, 2027 | 304d | $10.00 | +0.00% | 1 | 1 |
| Nov 19, 2027 | 395d | $10.60 | +2.91% | 1 | 3 |
| Jan 21, 2028 | 458d | $8.75 | -1.02% | 5 | 8 |
| Mar 17, 2028 | 514d | $10.82 | +0.00% | 50 | 31 |
| Jan 19, 2029 | 822d | $10.05 | +0.00% | 1 | 1 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.